Intent to Sole Source Ga68 Dotate NETSPOT - Base plus 4 option years
Award Notice Posted
- Solicitation number
- 36C24725Q0766
- Agency
-
Veterans Integrated Service Network 7
Veterans Health Administration, Department of Veterans Affairs
- Awarded
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- 36C24725P0870
- NAICS code
- 325413 In-Vitro Diagnostic Substance Manufacturing
- PSC
- Q517 Pharmacy Services
- Place of performance
- Georgia 30904, United States
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 7 awarded a sole source contract to Cardinal Health, Inc. for the supply of Ga-68 Dotatate NETSPOT injectable, a radiopharmaceutical used in Positron Emission Tomography (PET) imaging to identify neuroendocrine tumors in patients. The firm fixed price contract is valued at $302,250 and covers a five-year period from October 1, 2025 through September 30, 2030, supporting the Charlie Norwood VA Medical Center in Augusta, Georgia. This specialized molecular imaging agent enables medical professionals to locate somatostatin receptor positive neuroendocrine tumors throughout the body using PET/CT imaging technology. The VA issued an intent to sole source notice prior to award, allowing other potential vendors until July 25, 2025 to demonstrate their capability to meet the requirements, though the procurement ultimately proceeded as a sole source acquisition to Cardinal Health.
Notice text
***INTENT TO SOLE SOURCE NOTICE***
Estimated Date of Award: 1 Oct, 2025 Synopsis: Department of Veterans Affairs (VA) Network Contracting Office 7 (NCO 7) intends to award a sole source contract award to Cardinal Health, Inc., 7000 Cardinal Pl. Dublin, OH 43017-1091. The period of performance for contract award will be from October 1, 2025 through September 30, 2030. This requirement is for the purchase of Ga-68 Dotatate Netspot injectable Positron Emission Tomography imaging (PET) to identify suspected tumors in the body. Ga-68 Netspot is a PET/CT imaging radiopharmaceutical for the localization of somatostatin receptor positive neuroendocrine tumors. This injectable drug is a molecular imaging agent used in Positron Emission Tomography (PET) imaging to identify suspected NET tumors anywhere in the body. This will be a new firm fixed price contract supporting the Charlie Norwood VA Medical Center, located at 1 Freedom Way, Augusta, GA 30904. THIS NOTICE IS NOT A REQUEST FOR COMPETITIVE QUOTES; however, any firm that believes it can meet the requirements may give written notification prior to the response due date and time. Supporting evidence must be furnished in sufficient detail to demonstrate the ability to perform the requirements. Responses received will be evaluated; however, a determination by the Government not to compete the proposed procurement based upon responses to this notice is solely within the discretion of the Government. If no responses are received, the Government will proceed with the award. Responses are due by July 25, 2025 at 11:00 a.m. (ET). Responses shall be submitted via e-mail to Michael.barton@va.gov. Telephone requests or inquires will not be accepted. System for Award Management (SAM): Rule requires a firm to be registered in the SAM Registration Database (SAM) prior to award of any contract and agreements. Firms must register on an on-time basis, and annually confirm accuracy and completeness of registration information. To register in SAM go to: https://www.sam.gov/portal/public/SAM
Awarded contract 36C24725P0870 to Cardinal Health, Inc. for 302250.00 on 2025-10-01.
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| 6505--FY27 Low Energy General Radiopharmaceuticals 36C25027Q0052 | Veterans Integrated Service Network 10 | No set-aside |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity